Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) represent a popular platform for regenerative medicine due to their ability to home to damaged organs and secrete molecules that promote cell growth and suppress inflammation; however, there remains a need to optimize their therapeutic effect for clinical translation.

Due to the increasing awareness in the cell therapy community of a need to better understand the biology of transplanted cells in the myocardium, researchers led by Martin Rodriguez‐Porcel

Although mesenchymal stem cells (MSCs) offer enormous potential in the treatment of diseases associated with an aberrant immune system, the lack of information regarding the precise mechanism of action currently hampers the development of efficient and reproducible immune therapies.

A study describes how the RhoA/ ROCK1/β‐catenin signaling pathway aids the regulation of adipocytic and osteoblastic differentiation of mesenchymal stem cells by Lpar4

Researchers led by Mauro Krampera (University of Verona, Italy) recently focused on the immunological characterization of extracellular vesicles (EVs) derived from human bone marrow mesenchymal stem cells (MSCs) regarding their capability to induce regulatory T‐cells (T‐regs) in vitro and in a xenograft mouse model of graft-versus-host-disease (GvHD).

The enhancement of glymphatic function by mesenchymal stem cell therapy improves the distribution and efficacy of mutant huntingtin targeting antisense oligonucleotides

In vivo analysis identifying both tendon stem cells and the cells behind fibrotic scarring may aid the construction of enhanced tendon regeneration approaches

Cerebral adrenoleukodystrophy (CALD), characterized by imaging findings of demyelination, inflammation, and contrast enhancement on magnetic resonance imaging, suffers from a lack of accepted therapies for patients with advanced forms of the disease.

New findings provide evidence of the potential relevance of intranasal delivery of umbilical cord MSCs in the treatment of bronchopulmonary dysplasia patients

Appraisal of a well-characterized stem cell line in stroke models prompts a trial of intracarotid artery mesenchymal stem cell transplantation in ischemic stroke patients